FDA Approves YESINTEK — Biocon Biologics Inc.

Biocon Biologics Inc. announced the FDA approval of YESINTEK (ustekinumab) for the treatment of moderate-to-severe plaque psoriasis, a strategic expansion into the lucrative autoimmune market that leverages the existing success of key competitors. While the approval itself is significant, investor sentiment is likely to focus more on the biosimilar's anticipated price positioning and the company's ability to capture share against established market leaders like Janssen.